Voyager Therapeutics (VYGR) Gains from Sales and Divestitures (2016 - 2025)
Voyager Therapeutics (VYGR) has disclosed Gains from Sales and Divestitures for 10 consecutive years, with $691107.0 as the latest value for Q4 2025.
- Quarterly Gains from Sales and Divestitures rose 34.12% to $691107.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $691107.0 through Dec 2025, up 34.12% year-over-year, with the annual reading at $691107.0 for FY2025, 34.12% up from the prior year.
- Gains from Sales and Divestitures hit $691107.0 in Q4 2025 for Voyager Therapeutics, up from $568331.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $691107.0 in Q4 2025 to a low of $184217.0 in Q1 2021.
- Historically, Gains from Sales and Divestitures has averaged $416912.0 across 5 years, with a median of $421680.5 in 2022.
- Biggest five-year swings in Gains from Sales and Divestitures: skyrocketed 129.71% in 2021 and later decreased 13.33% in 2024.
- Year by year, Gains from Sales and Divestitures stood at $326943.0 in 2021, then surged by 33.54% to $436611.0 in 2022, then rose by 21.75% to $531560.0 in 2023, then dropped by 3.06% to $515303.0 in 2024, then surged by 34.12% to $691107.0 in 2025.
- Business Quant data shows Gains from Sales and Divestitures for VYGR at $691107.0 in Q4 2025, $568331.0 in Q3 2025, and $550084.0 in Q2 2025.